Cell Therapy Catapult and CRC for Cell Therapy Manufacturing have entered a co-development agreement to optimise and develop the existing cell expansion processes.
Pursuant to the agreement, the two companies will further develop scaffold technology for the T-cell stimulation, expand to apply it in the commercial-scale production, and develop a platform to generate large number of T-cells for cell-based immunotherapies for conditions such as cancer and autoimmune diseases.
Evercyte has entered a co-development agreement with VTU Technology to develop media supplements, including growth factors and cytokines.
Under the agreement, VTU Technology will be responsible for the production of recombinant products utilising its proprietary Pichia technology.
Thunderbolt Pharma, a company established by Vitesse Biologics, has acquired all rights to BAFF / APRIL dual antagonist programme from Astellas Pharma, a pharmaceutical company focused on research, development, manufacturing and commercialisation.
Thermabolt Pharma will utilise the BAFF / APRIL programme to develop treatments for systemic lupus erythematosus and other B-cell mediated disorders.
Noden Pharma DAC has announced that it will raise funds amounting to approximately $107m through private placement of shares, which will be subscribed to by PDL Biopharma.
The company has further announced its plans to invest the raised funds in the acquisition of worldwide rights of Tekturna (aliskiren) and Tekturna HCT (aliskiren and hydrochlorothiazide) products from Novartis AG.
Albertsons Companies and its subsidiaries have announced an offering of senior notes due 2024. The co-issuing subsidiaries include Safeway Inc., New Albertson’s, Inc. and Albertson’s LLC.
The companies plan to utilise the funds to primarily pay the redemption price and accrued and unpaid interest in connection with the redemption of all outstanding 7.75% senior notes due in 2022, and repay an existing term loan.
The companies expect to raise gross proceeds of $1.25bn through the offering.
